

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

<https://marketpublishers.com/r/C8F748F7E759EN.html>

Date: May 2022

Pages: 292

Price: US\$ 5,000.00 (Single User License)

ID: C8F748F7E759EN

Abstracts

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

Contents

1. EXECUTIVE SUMMARY

2. RECOMBINANT VACCINES MARKET

- 2.1. Product Overview
- 2.2. Market Definition
- 2.3. Segmentation
- 2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

- 3.1. Research Objectives
- 3.2. Primary Research
- 3.3. Secondary Research
- 3.4. Forecast Model
- 3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MARKET DYNAMICS

- 5.1. Growth Drivers
- 5.2. Restraints
- 5.3. Opportunity
- 5.4. Trends

6. CORRELATION & REGRESSION ANALYSIS

- 6.1. Correlation Matrix
- 6.2. Regression Matrix

7. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE

8. RISK ANALYSIS

- 8.1. Demand Risk Analysis
- 8.2. Supply Risk Analysis

9. RECOMBINANT VACCINES MARKET ANALYSIS

9.1. Porters Five Forces

- 9.1.1. Threat of New Entrants
- 9.1.2. Bargaining Power of Suppliers
- 9.1.3. Threat of Substitutes
- 9.1.4. Rivalry

9.2. PEST Analysis

- 9.2.1. Political
- 9.2.2. Economic
- 9.2.3. Social
- 9.2.4. Technological

10. RECOMBINANT VACCINES MARKET

10.1. Market Size & forecast, 2019A-2030F

- 10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION

11.1. By Regions

- 11.1.1. North America:(U.S. and Canada)
 - 11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
 - 11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
 - 11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
 - 11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- 11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
 - 11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION

12.1. By technology: Market Share (2020-2030F)

12.1.1. conjugate vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.2. inactivated and subunit vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.3. live attenuated vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.4. recombinant vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.1.5. toxoid vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.2. By patient type : Market Share (2020-2030F)

12.2.1. pediatric, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12.2.2. adult patients, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

13. COMPANY PROFILE

13.1. Johnson and Johnson

13.1.1. Company Overview

13.1.2. Company Total Revenue (Financials)

13.1.3. Market Potential

13.1.4. Global Presence

13.1.5. Key Performance Indicators

13.1.6. SWOT Analysis

13.1.7. Product Launch

13.2. Abiomed

13.3. Emergent Bio Solutions, Inc.

13.4. GlaxoSmithKline

13.5. Sanofi Pasteur SA

13.6. Serum Institute of India Pvt. Ltd

13.7. Mitsubishi Tanabe Pharma Corporation

13.8. Daiichi Sankyo

13.9. Pfizer, Inc.

13.10. Other prominent players

Consultant Recommendation

**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

I would like to order

Product name: COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

Product link: <https://marketpublishers.com/r/C8F748F7E759EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8F748F7E759EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970